Results from the PIONEER clinical trials program indicate that the first oral glucagon-like peptide-1 receptor agonist (GLP-1RA), oral semaglutide, provides effective glycemic control across a range of different patient populations.
Click PLAY to watch the video abstract.
Click here to watch the full supplement infographic.
Click here to read full article to this video abstract.